Full Text View
Tabular View
No Study Results Posted
Related Studies
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
This study is ongoing, but not recruiting participants.
Study NCT00003283   Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999   Last Updated: July 23, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Thymoma and Thymic Carcinoma
Additional conditions recognized in this trial
Carcinoma
Thymoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Complex and Mixed
Neoplasms, Glandular and Epithelial
Thoracic Neoplasms
Thymus Neoplasms
Interventions listed in this trial
octreotide acetate
prednisone
Additional drug interventions recognized in this trial
Octreotide
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services